Clinical trial

January 3, 2021 Prasad Ravindranath

Why people with prior SARS-CoV-2 infection still need to be vaccinated

Since vaccine shortage is expected to last at least for a few months, it may seem appealing to delay or

Clinical trial Coronavirus COVID-19 Public Health Public health policy SARS-CoV-2 Vaccines

January 2, 2021 Prasad Ravindranath

UK uses an untested strategy to rapidly but partially protect people at risk

With the virus running amok in the country and vaccines in short-supply, the U.K. is attempting an untested strategy of delaying the second dose of both AstraZeneca and Pfizer vaccine even in the absence of data from large trials. The intent is to rapidly but partially protect more individuals who are at risk.

Clinical trial Coronavirus Public Health SARS-CoV-2 Vaccines

December 11, 2020 Prasad Ravindranath

By putting the vaccine approval on hold for want of data, DCGI has underscored its priorities

The greatly reassuring decision to seek additional safety and immunogenicity data from the Pune-based Serum Institute of India and Hyderabad’s

Clinical trial Coronavirus COVID-19 Public Health SARS-CoV-2 Vaccines

December 8, 2020 Prasad Ravindranath

Transparency in COVID-19 vaccine trials vital to gain public trust

Unlike Pfizer, AstraZeneca, which is carrying out the phase-3 trials of the Oxford vaccine in four countries, is yet to

Clinical trial Coronavirus FDA Public Health SARS-CoV-2 Vaccines

December 1, 2020 Prasad Ravindranath

Moderna’s mRNA vaccine has 94.1% efficacy in final analysis, has applied for EUA

According to the release, the Phase-3 trial has exceeded two months of median follow-up post vaccination as required by the U.S. FDA

Clinical trial Coronavirus Public Health SARS-CoV-2 Vaccines

November 23, 2020 Prasad Ravindranath

Oxford vaccine shows 90% efficacy in Phase-3 trial

Two doses of the vaccine given in two different regimen showed different efficacies. In the case of the regimen (involving

Clinical trial Coronavirus Ethics Public Health SARS-CoV-2 Vaccines

November 22, 2020 Prasad Ravindranath

Ethics of denying COVID-19 vaccine to placebo group participants once EUA is granted

Offering the vaccine right away to those in the placebo group will first require unblinding the study. Unblinding the study and offering the vaccine to the placebo group will make it almost impossible to gather further information on vaccine efficacy, thus making full licensure challenging.